Segmental Details As of the second quarter of 2019, QIAGEN has two major customer classes which are Molecular Diagnostics (that includes human healthcare including Precision Medicine and companion diagnostics) and Life Sciences (that includes Pharma and Academia/Applied Testing). Molecular diagnostics (representing 49% of net sales) revenues were up 5% at CER to $188 million. Life Sciences (51% of total revenues) reported revenues of $194 million, up 5% at CER. Sales derived from Applied Testing/Academia rose 5% at CER to $118 million. Pharma sales climbed 4% at CER in the second quarter to $76 million. Operational Update Gross profit in the quarter under review declined 3.1% to $245.9 million. Gross margin contracted 283 basis points (bps) to 64.4%. Adjusted operating income (excluding items like acquisition-related intangible amortization) rose 8.6% year over year to $68.9 million in the second quarter. Adjusted operating margin expanded 124 bps to 18%.